Exciting news in the fight against HPV-related cancers, GARDASIL 9 is now available
GARDASIL 9 helps protect against 9 types of HPV (6, 11, 16, 18, 31, 33, 45, 52 & 58), five more types than the previous Quadrivalent Vaccine (1,2).
Helping protect patients against more HPV related cancers, including cervical, vaginal and anal cancers. Gardasil 9 also helps protect against genital warts (1).
From 1 January 2017, GARDASIL 9 was funded for males and females aged 9-26 years old (3).
Make sure your practice is ready
Find out more about what GARDASIL 9 means for your practice and patients. Order resources or book a visit from a Seqirus representative today and make sure you’re ready.
You can also download the Gardasil 9 Datasheet here.
*compared to Quadrivalent HPV Vaccine. References 1. Gardasil 9 Data sheet 2. Gardasil Data Sheet 3. PHARMAC. Changes to the National Immunisation Schedule. 28 July 2016.
*GARDASIL® 9 [9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Recombinant vaccine] Gardasil 9 is funded for both males and females aged 9-26 years. A patient charge will apply for all others outside this age range. Please refer to the PHARMAC funding criteria for more details. PRESENTATION: 0.5mL pre-filled syringe containing the following approximate amounts of L1 protein: 30 mcg of HPV 6; 40 mcg of HPV 11; 60 mcg of HPV 16; 40 mcg of HPV 18; 20 mcg of HPV 31; 20 mcg of HPV 33; 20 mcg of HPV 45; 20 mcg of HPV 52; and 20 mcg of HPV 58. INDICATIONS: Females aged 9 to 45 years: prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58. Males aged 9 to 26 years: prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58. CONTRAINDICATIONS: Hypersensitivity to any GARDASIL or GARDASIL 9 ingredients; hypersensitivity developed after a dose of GARDASIL or GARDASIL 9. PRECAUTIONS AND WARNINGS: Syncope, current or recent febrile illness, impaired immune responsiveness, thrombocytopenia, coagulation disorder, pregnancy (B2), children under 9 years old, elderly, and HIV infection. INTERACTIONS: Systemic doses of corticosteroids, irradiation, antimetabolites, alkylating agents, cytotoxic agents. ADVERSE REACTIONS: Injection site reactions (pain, swelling, erythema, pruritus, haematoma, haemorrhage, induration and warmth), headache, pyrexia, nausea, dizziness, fatigue, diarrhoea, myalgia, oropharyngeal pain, upper abdominal pain, upper respiratory tract infection, asthmatic crisis, cellulitis, idiopathic thrombocytopenic purpura, lymphadenopathy, acute disseminated encephalomyelitis, Guillain-Barré syndrome, syncope sometimes with tonic-clonic movements, hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm and urticaria. DOSAGE AND ADMINISTRATION: GARDASIL 9 should be administered intramuscularly. The first dose on day 0; the second and third doses at 2 months and 6 months after the first dose respectively. Alternatively, for children aged 9 through 14: two separate intramuscular doses. The first dose on day 0 and the second at least 5 and no more than 13 months after the first dose. MEDICINE CLASSIFICATION: Prescription Medicine. Before prescribing review GARDASIL 9 data sheet (dated 27 June 2016) at www.medsafe.govt.nz or www.seqirus.co.nz. Seqirus (NZ) Ltd, Auckland. GARDASIL® 9 is a registered trademark of Merck & Co. Inc., Whitehouse Station, NJ, 08889 USA.